UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM SD
SPECIALIZED DISCLOSURE REPORT
AbbVie Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-35565 |
|
32-0375147 |
|
(State or other Jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
|
of Incorporation) |
|
|
|
Identification No.) |
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
William J. Chase (847) 932-7900
(Name and telephone number, including area code, of the person to contact in connection with this report.)
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
x Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2017.
SECTION 1 — CONFLICT MINERALS DISCLOSURE
Item 1.01. Conflict Minerals Disclosure and Report
The Conflict Minerals Report for AbbVie Inc. (AbbVie) for the year ended December 31, 2017 is attached as Exhibit 1.01 to this Report and is available on AbbVie’s website at www.abbvieinvestor.com.
Item 1.02. Exhibit
AbbVie’s Conflict Minerals Report is attached as Exhibit 1.01 to this Report.
SECTION 2 — EXHIBITS
Item 2.01. Exhibits
|
Exhibit No. |
|
Description |
|
Exhibit 1.01 |
|
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
|
AbbVie Inc. | |||
|
(Registrant) | |||
|
| |||
|
|
|
|
|
|
By: |
/s/ William J. Chase |
|
Date: May 31, 2018 |
|
|
William J. Chase |
|
|
|
|
Executive Vice President, Chief Financial Officer |
|
|